Louise Rodino-Klapac
Analyst
Chief Scientist
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Louise Rodino-Klapac
Louise Rodino-Klapac is recorded as Analyst at Chief Scientist. Sarepta Therapeutics, Inc. reported in an 8-K filed July 16, 2025 that Louise Rodino-Klapac was appointed President, Research and Development and Technical Operations, effective July 16, 2025. The proxy statement of Sarepta Therapeutics, Inc. reports total compensation of $4,456,270 for Louise Rodino-Klapac in fiscal 2025, including a base salary of $752,505. Disclosed compensation is on record for 8 fiscal years. Louise Rodino-Klapac has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Sarepta Therapeutics, Inc. on August 5, 2026.
“On July 14, 2025, the Board appointed Ian Estepan as the Company's President and Chief Operating Officer, Louise Rodino-Klapac, Ph.D. as the Company's President, Research and Development and Technical Operations, and Ryan Wong as the Company's Executive Vice President, Chief Financial Officer, each effective as of July 16, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Sarepta Therapeutics, Inc. (SRPT)
Proxy statement
CurrentStart not stated–present
-
Chief Scientist
Analyst
Source not stated
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Sarepta Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Douglas Ingram CEO, Board Member
- Michael Severino, M.D. CEO, Board Member
- M. Kathleen Behrens Chairman
- Ryan H. Wong CFO
- Ian Estepan COO, Chief Accounting Officer
- Ian M. Estepan COO
- Cristin L. Rothfuss General Counsel
- Claude Nicaise Board Member
- Claude Nicaise, M.D. Board Member
- Deirdre Connelly Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sarepta Therapeutics, Inc. (SRPT) | President, Research and Development and Technical Operations | $752,505 | $4,456,270 |
| 2024 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $666,706 | $2,737,283 |
| 2023 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $641,063 | $3,718,991 |
| 2022 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $616,962 | $3,941,777 |
| 2021 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer | $555,577 | $8,515,533 |
| 2020 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | $495,590 | $7,269,883 |
| 2019 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | — | — |
| 2018 | Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President, Chief Scientific Officer ^^ | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.